The USFDA has issued final guidance to improve patient communication regarding the labeling recommendations of breast implants. The FDA has also recommended changes in the format and content regarding the labeling of breast implants to help improve the information available to patients. Information on the risks and benefits of breast implants will help them make informed decisions.
Over the past few years, the USFDA has received new information on the risks associated with breast implants such as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and breast implant illness with systemic symptoms like brain fog, fatigue, joint or muscle pain, and rash. The FDA has convened the General and Plastic Surgery Devices Advisory Panel in 2019 to discuss the long-term benefits and risks associated with breast implants for breast augmentation and reconstruction. Some of the…
